Hair Loss Clinical Trial
Official title:
A Single-Group Clinical Trial Investigating the Effects of a Hair Vitamin Combination on Hair Growth and Hair Health
NCT number | NCT06120933 |
Other study ID # | 20354 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 15, 2023 |
Est. completion date | October 6, 2023 |
Verified date | November 2023 |
Source | BrandiZone |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial aims to investigate the effectiveness of two Vitamins Revive hair supplements in promoting hair growth, reducing hair loss, and improving overall hair health. The products under assessment are Hair Nutra Growth and Hair Nutra Boost. The trial will assess the efficacy of the products to induce better hair growth, reduction in hair loss and shedding, increased hair thickness and fullness, and improvement in hair appearance and vitality over a 12-week testing period. Participants will complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12. Participants will also provide photos of their hair at Baseline, Week 4, Week 8, and Week 12.
Status | Completed |
Enrollment | 25 |
Est. completion date | October 6, 2023 |
Est. primary completion date | October 6, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 30 Years and older |
Eligibility | Inclusion Criteria: - Women Aged 30+ Self-reported issues with hair growth, shedding, and thinning Generally healthy - don't live with any uncontrolled chronic disease Must be willing to stop taking any other hair growth supplements or biotin supplements for the duration of the trial In the last three months, has not introduced any new supplements or medications to target hair growth, hair loss, or hair health Individuals must agree to refrain from dyeing their hair in the target interest areas until the study is complete Willing and able to take high-quality photographs of their hairline Exclusion Criteria: - Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders Anyone with known severe allergic reactions Anyone with a known allergy to any of the ingredients Anyone currently using a hair growth supplement Anyone currently using biotin Anyone with scalp or hair diseases including but not limited to alopecia areata (a hair loss disorder leading to patchy bald spots on the head) Women who are pregnant, breastfeeding, or attempting to become pregnant Unwilling to follow the study protocol |
Country | Name | City | State |
---|---|---|---|
United States | Citruslabs | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
BrandiZone | Citruslabs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in hair thickness. [Timeframe: Baseline to Week 12] | Changes in participants' perception of their hair thickness will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). | 12 weeks | |
Other | Changes in hair shine. [Timeframe: Baseline to Week 12] | Changes in participants' perception of their hair shine will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). | 12 weeks | |
Other | Changes in hair softness. [Timeframe: Baseline to Week 12] | Changes in participants' perception of their hair softness will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). | 12 weeks | |
Other | Changes in hair vitality. [Timeframe: Baseline to Week 12] | Changes in participants' perception of their hair vitality will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). | 12 weeks | |
Primary | Changes in self-reported rate of hair growth. [Timeframe: Baseline to Week 12] | Changes in self-reported rate of hair growth will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). | 12 weeks | |
Primary | Changes in self-reported rate of hair loss. [Timeframe: Baseline to Week 12] | Changes in rate of hair loss will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Changes in self-reported rate of hair loss | 12 weeks | |
Primary | Changes in hair shedding. [Timeframe: Baseline to Week 12] | Changes in hair shedding will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). | 12 weeks | |
Secondary | Changes in participant-percieved overall hair health. [Timeframe: Baseline to Week 12] | Changes in participants perception of their overall hair health will be recorded via study-specific questionnaires. Responses will be on a Likert scale (0-5 scale), with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05019066 -
Oral Herbal Combination Formulation and Hair Growth in Women
|
N/A | |
Recruiting |
NCT05502796 -
Natural History and Pathogenesis of Alopecia in Children and Adults
|
||
Completed |
NCT00981461 -
Treatment of Androgenetic Alopecia in Females, 9 Beam
|
N/A | |
Terminated |
NCT03709563 -
Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
|
N/A | |
Completed |
NCT06095739 -
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
|
N/A | |
Completed |
NCT03351322 -
ENERGI-F701 for Female Hair Loss Treatment
|
Phase 2 | |
Recruiting |
NCT06215469 -
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
|
N/A | |
Completed |
NCT05945979 -
Evaluation of the Efficacy of a New Supplement for Hair and Nails - in Vitro, Clinical, Subjective and Instrumental Study
|
N/A | |
Not yet recruiting |
NCT05484973 -
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
|
N/A | |
Recruiting |
NCT05319444 -
Cleansing Device for the Treatment of Scalp and Hair Conditions
|
N/A | |
Withdrawn |
NCT04379583 -
HairDx Analytical Validation Study
|
||
Recruiting |
NCT05970809 -
Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss
|
N/A | |
Completed |
NCT00947219 -
Treatment of Androgenic Alopecia in Males
|
N/A | |
Not yet recruiting |
NCT03155958 -
Ocular Finding in Alopecia Areata
|
N/A | |
Enrolling by invitation |
NCT06174441 -
The Effect of 24-week Dietary Intake of Food Supplements on Hair
|
N/A | |
Unknown status |
NCT02393040 -
Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia
|
N/A | |
Completed |
NCT01016964 -
Treatment of Androgenetic Alopecia in Females, 12 Beam
|
N/A | |
Recruiting |
NCT06283316 -
Systemic Treatments for Alopecia Areata Registry
|
||
Completed |
NCT04249128 -
Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)
|
Phase 3 | |
Recruiting |
NCT06117293 -
Safety and Efficacy Evaluation of the Mosaic Ultra Device
|
N/A |